soliris
alexion europe sas - eculizumab - hemoglobinuria, paroxística - inmunosupresores - soliris está indicado en adultos y niños para el tratamiento de:la hemoglobinuria paroxística nocturna (hpn). evidencia de beneficio clínico se ha demostrado en pacientes con hemólisis con síntoma clínico(s) indicativo de la alta actividad de la enfermedad, independientemente de los antecedentes de transfusión (véase la sección 5. atípico síndrome hemolítico urémico (ahus). soliris está indicado en adultos para el tratamiento de:miastenia gravis generalizada refractaria (gmg) en los pacientes que son anti-receptor de acetilcolina (achr) anticuerpo-positivos (véase la sección 5. neuromielitis óptica trastorno del espectro (nmosd) en los pacientes que están en contra de la acuaporina-4 (aqp4) anticuerpo-positivos con un curso recidivante de la enfermedad.
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxística - inmunosupresores selectivos - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
iris versicolor d6 comprimidos
knop laboratorios s.a. - sin formulas
aliviho®– cefalea
empresa laboratorios aica. unidad empresarial de base (ueb) "laboratorio julio trigo". - tintura madre homeopática a partir de las reglas de preparación hahnemannianas 1/100 de : atropa belladonna 30 ch, bryonia alba 15 ch, cyclamen europaeum 15 ch, gelsemium sempervirens 15 ch, glonoinum 12 ch, iris versicolor 12 ch, natrum muriaticum 9 ch, sanguinaria canadensis 15 ch, spigelia anthelmia 15 ch - gotas sublinguales - 9-30 ch
soliris 300 mg vial 30 ml
ultomiris solución concentrada para solución para perfusión 300 mg/ 30 ml (ravulizumab)
astrazeneca s.a. - ravulizumab - sin formulas
irisovir 3% ungüento oftálmico
grupo paill, s.a. de c.v. - ungüento oftalmico - 3%
iristimol 5 mg/ml solución oftálmica
grupo paill, s.a. de c.v. - solución oftálmica - 5 mg/ml
kairison vast.desm.arriba.
b. braun medical peru s.a. -
ultomiris®
alexion pharmaceuticals inc estados unidos - cada ml contiene: ravulizumab??.100 mg/ml - concentrado para solución para perfusión - cada ml contiene: ravulizumab??.100 mg/ml